StockData
Ironwood Pharmaceuticals Inc logo

Ironwood Pharmaceuticals Inc (IRWD) stock

IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.78−0.09 (-1.85%)

Close on Nov 18, 2026Market cap $789.85MP/E 6.2Yield –

Ironwood Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Ironwood Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $185.56M, up 518.8% year over year. For fiscal 2025 it was $127.04M, up 22.7% from the year before. The highest annual figure on record is $273.76M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$127.04M+22.7%
FY2024Dec 31, 2024$103.55M-43.5%
FY2023Dec 31, 2023$183.43M-33.0%
FY2022Dec 31, 2022$273.76M+4.5%
FY2021Dec 31, 2021$261.90M+55.1%
FY2020Dec 31, 2020$168.84M+1474.2%
FY2019Dec 31, 2019$10.73M–
FY2018Dec 31, 2018-$70.88M–
FY2017Dec 31, 2017-$100.75M–
FY2016Dec 31, 2016-$25.93M–
FY2015Dec 31, 2015-$106.93M–
FY2014Dec 31, 2014-$155.57M–
FY2013Dec 31, 2013-$273.36M–
FY2012Dec 31, 2012-$69.63M–
FY2011Dec 31, 2011-$75.24M–
FY2010Dec 31, 2010-$67.90M–
FY2009Dec 31, 2009-$3.45M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$58.28M–
Q1 FY2026Mar 31, 2026$5.12M-74.3%
Q4 FY2025Dec 31, 2025$74.58M+390.2%
Q3 FY2025Sep 30, 2025$47.58M+381.4%
Q2 FY2025Jun 30, 2025-$15.07M-145.0%
Q1 FY2025Mar 31, 2025$19.95M-55.6%
Q4 FY2024Dec 31, 2024$15.21M-57.5%
Q3 FY2024Sep 30, 2024$9.89M-69.5%
Q2 FY2024Jun 30, 2024$33.47M-4.3%
Q1 FY2024Mar 31, 2024$44.99M-43.9%
Q4 FY2023Dec 31, 2023$35.83M-54.7%
Q3 FY2023Sep 30, 2023$32.46M-53.0%
Q2 FY2023Jun 30, 2023$34.96M-43.0%
Q1 FY2023Mar 31, 2023$80.17M+25.0%
Q4 FY2022Dec 31, 2022$79.18M+22.6%
Q3 FY2022Sep 30, 2022$69.09M-8.0%
Q2 FY2022Jun 30, 2022$61.37M+26.3%
Q1 FY2022Mar 31, 2022$64.12M-13.0%
Q4 FY2021Dec 31, 2021$64.57M+25.3%
Q3 FY2021Sep 30, 2021$75.07M+40.0%
Q2 FY2021Jun 30, 2021$48.57M+141.8%
Q1 FY2021Mar 31, 2021$73.69M+69.0%
Q4 FY2020Dec 31, 2020$51.51M+86.8%
Q3 FY2020Sep 30, 2020$53.63M+54.3%
Q2 FY2020Jun 30, 2020$20.09M–
Q1 FY2020Mar 31, 2020$43.60M–
Q4 FY2019Dec 31, 2019$27.58M+197.4%
Q3 FY2019Sep 30, 2019$34.77M–
Q2 FY2019Jun 30, 2019-$9.24M–
Q1 FY2019Mar 31, 2019-$42.39M–
Q4 FY2018Dec 31, 2018$9.27M–
Q3 FY2018Sep 30, 2018-$26.58M–
Q2 FY2018Jun 30, 2018-$22.69M–
Q1 FY2018Mar 31, 2018-$30.89M–
Q4 FY2017Dec 31, 2017-$9.21M–
Q3 FY2017Sep 30, 2017-$31.24M–
Q2 FY2017Jun 30, 2017-$32.45M–
Q1 FY2017Mar 31, 2017-$27.85M–
Q4 FY2016Dec 31, 2016-$19.19M–
Q3 FY2016Sep 30, 2016-$645.00K–

More Ironwood Pharmaceuticals figures

See a number that looks wrong?